And just to be silly - Everything in Reverse!

Might as well stretch things out further by running everything in reverse as well:

T-Shirt/Mug Design ca 1987



(c) 1987, 2013 The Animation Apothecary



The t-shirts recycled, the mugs all broken -- it may be time to run with CafePress now!

Mug Design #1 - Mr Caffeine for President

Everyone else is getting ready for 2016, so why not Mr. Caffeine?



(c) 1988, 2013 The Animating Apothecary



Coming soon from cafepress....maybe too soon...
In the meantime...
See the first volume of sketches at http://www.lulu.com/shop/jim-middleton/uncle-stans-profusely-illustrated-world-no-1/paperback/product-20701680.html

First Compilation - Uncle Stan's Profusely Illustrated World #1

 OK, it's lulu press, but it's finally done.  Another three expected in the series before the scanner fries....

(c) 2013 The Animating Apothecary

36 pages, black and white illustrations at Lulu Press
http://www.lulu.com/spotlight/UncleStan

Here's the cover for the second set of sketches, assembly complete at at LULU:

http://www.lulu.com/spotlight/UncleStan

Bad Pun Department

More fooling around with Photoshop:



(c) 2006 The Animating Apothecary

lulu press link:  http://ar.gy/3UB9

Winning the Lottery - American Style

From a pre-1990 calendar...finally got around to colorizing it.  Lovin' that Photoshop!

(c) 1989 The Animating Apothecary

See the whole first volume! http://www.lulu.com/shop/jim-middleton/uncle-stans-profusely-illustrated-world-no-1/paperback/product-20701680.html

In spite of popular demand - the 2013 Late Edition Calendar!

Cover of the out of print 2013 edition, in full expensive Technicolor (TM).  OK, not really.  Just in color. 

(c) 2013, The Animating Apothecary

Coming Soon to a Checkout Counter Near YOU!

From the 1994 Calendar:


(c) 1993 The Animating Apothecary



lulu press link:  http://ar.gy/3UB9

An R Crumb Moment, 2000

Inspired while at the 2000 Ottawa Animation Festival.  The two were seated near the program auditorium when I arrived for registration at 8am, and they were still at the same bench when I took an afternoon break at 4. 

Illustration compilation at lulu press.  Here's the link:  http://ar.gy/3UB9

Happy Holidays from the Animating Apothecary!



(c) 1997 The Animating Apothecary

 See the whole first volume! http://www.lulu.com/shop/jim-middleton/uncle-stans-profusely-illustrated-world-no-1/paperback/product-20701680.html

Coming Soon to a T-Shirt Near You

(c) 1987 The Animating Apothecary

...or a coffee mug...
...needs some Photoshop TLC...

A Day in the Life - 1999

(c) 1999 Animating Apothecary

Why There Are Few Real "New" Drugs

(c) 2003 Animating Apothecary/Jim Middleton



(c) 2003 The Animating Apothecary/Jim Middleton

The FDA Steps Up to Control Narcotic Deaths -- well....

Annual deaths associated with acetaminophen toxicity run about 450 per year.  In 2007, over 11,500 died from hydrocodone toxicity.  Vicodin, Norco, and Lorcet are all combinations of hydrocodone and acetaminophen and are not only heavily abused, but are also implicated in greater numbers of 'accidental deaths' (meaning, abusers who don't make the statistic are accidentally living) each year.
The FDA's response - restrict the amount of acetaminophen in each tablet!
The corporate response?  Abbott, now owners of the Vicodin 'brand' stepped up and made a change in their formulation - no more than 300mg of acetaminophen per tablet (they had allowed up to 750mg per tablet before).  This makes a 'new drug' according to the FDA (a tactic employed by the makers of Tussionex cough syrup for years), and makes previously available 'generics' for 'brand name' Vicodin no longer 'equivalent.'
So a generic company stepped up, got the first approval for a 'generic' and lo - another example of the FDA helping contribute to the rising expense of health care!

The wholesale price of $148.27 is for 100 tablets of this 'generic' for the 'reformulated' Vicodin ES.  Pharmacies could buy a LOT of the old generic, hydrocodone 7.5mg/acetaminophen 750mg for the same price.

2003 Flashback - Dubya's Health Care Plan

So much talk about Obama/O'Romneycare these days...what would that stellar intellect of just one administration ago have come up with?  Oh the possibilities, the possibilites...


(c) 2003 Jim Middleton The Animating Apothecary

Flashback Sketch - January 2003

A calendar template with only one possible use.  Experimenting with Art Nouveau...

A History of Pharmacy - Until 1997, at least...

See the whole first volume! http://www.lulu.com/shop/jim-middleton/uncle-stans-profusely-illustrated-world-no-1/paperback/product-20701680.html

A Rather Disturbing Trend in 'Medicine'

A recent link from "Physician's Money Digest" is as follows.   I find it at least disturbing that the article celebrates the profits that can be had in treating cancer, and how it can offer the information to physicians who might be willing to benefit from judicial investments.  I contend that a logical sequel to this would be a listing of the 10 Most Profitable Mortuary Chains.
Here's the article:
 
10 Best-Selling Cancer Drugs

Right now oncology is the main attraction, which makes sense considering ASCO is just two weeks away. But oncology drugs have always garnered a lot of attention because the diseases they treat are so scary for the patients, plus they can be quite costly. (italics mine)

But the good thing (for the pharmaceutical companies) is that these drugs aren’t facing generic competition like some other drugs have to. As a result, expensive and older treatments are contending with low-cost generics for sales, meaning they’re still bringing in a pretty penny for the company. (emphasis mine - again, what are we celebrating here?  More effective treatments?  Or more expensive - and thus, profitable - treatments for drug companies?  And are any of these treatments more effective, or just more profitable?  And isn't it just about the creepiest thing to consider success not by outcomes, or benefits to the patients, but as profit from sales of these drugs.... what a world, what a world... )

FiercePharma released a list of the top 10 best-selling cancer drugs based on how much they brought in U.S. sales over the last year. (My interruption again:  they also have a nice discussion on whether drug company CEOs get paid enough!!! So far their newsletter is free, so go there and get the daily scoop on what PharmaLand is doing behind the curtain)....

(And look how the information is presented, like it's some Top Ten on the David Letterman Show)

10. Tarceva
Company: Genentech
2011 sales: $564.2 million
FDA approvals: Non-small cell lung cancer, 2004; pancreatic cancer, 2005; NSCLC maintenance therapy, 2010.

9. Xeloda
Company: Genentech
2011 sales: $647.6 million
FDA approvals: Metastatic colorectal cancer, 1998; metastatic breast cancer, 2002; adjuvant colon cancer therapy, 2005.

8. Velcade
Company: Millennium Pharmaceuticals, a unit of Takeda Pharmaceutical Industries, in partnership with Johnson & Johnson
2011 sales: $692.7 million
FDA approvals: Multiple myeloma, 2003; mantle cell lymphoma, 2006; first-line multiple myeloma, 2008.

7. Erbitux
Company: Eli Lilly, in partnership with Bristol-Myers Squibb
2011 sales: $703.3 million
FDA approvals: EGFR-positive colorectal cancer, 2004; second line in head and neck cancer, 2006; first line in recurrent or metastatic head and neck cancer, 2011.

6. Alimta
Company: Eli Lilly
2011 sales: $1.04 billion
FDA approvals: Malignant pleural mesothelioma, 2004; non-small cell lung cancer, 2008; NSCLC maintenance therapy, 2009.

5. Eloxatin
Company: Sanofi
2011 sales: $1.2 billion
FDA approvals: Colorectal cancer, 2002; adjuvant use in colorectal cancer, 2004; new formulation, 2005.

4. Gleevec
Company: Novartis
2011 sales: $1.51 billion
FDA approvals: Chronic myelogenous leukemia, 2011; gastrointestinal stromal tumors, 2002; Philadelphia-chromosome positive acute lymphocytic leukemia, 2006; dermatofibrosarcoma protuberans, 2006; certain myelodysplastic/myeloproliferative diseases, 2006; hypereosinophilic syndrome/chronic eosinophilic leukemia, 2006; aggressive systemic mastocytosis, 2006; adjuvant GIST treatment, 2012.

3. Herceptin
Company: Genentech
2011 sales: $1.66 billion
FDA approvals: Metastatic HER2-positive breast cancer, 1998; adjuvant in early-stage HER2-positive breast cancer, 2006; additional adjuvant approvals, 2008; HER2-positive gastric or gastroesophageal junction cancer.

2. Avastin
Company: Genentech
2011 sales: $2.66 billion
FDA approvals: Metastatic colorectal cancer, 2004; non-small cell lung cancer, 2006; breast cancer, 2008 (revoked in 2011); kidney cancer, 2009; brain cancer, 2009.

AND HERE'S NUMBER ONE - The drumroll, please!!!!
1. Rituxan

Company: Genentech
2011 sales: $3 billion
FDA approvals: Non-Hodgkin lymphoma, 1997; rheumatoid arthritis symptoms, 2006; rheumatoid arthritis disease progression, 2008; chronic lymphocytic leukemia, 2010; Wegener's granulomatosis and microscopic polyangiitis, 2011.

Ka- CHING!!!!!!

Fallout from the Calendar archives...

That's about how I recall January of 2009....

Illustration compilation at lulu press.  Here's the link:  http://ar.gy/3UB9

Cryptic Holiday Greetings for 2011

Not sure what this means, exactly, but it appeared on the sketchbook during a broadcast of "It Happened on Fifth Avenue."  Therefore, it has a holiday theme....